Boston Scientific Corporation
NYSE:BSXMedical - Devices
+$0.45 today
- Market cap
- $63.25B
- Beta
- 0.56
- P/E (TTM)
- 19.0
- EPS (TTM)
- $2.39
Volume 13.21M
Average 19.45M
BSX Common Stock Issued
Cash raised by issuing new shares.
Boston Scientific CorporationNYSE: BSX
Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026
Common stock issued declines year over year
Q2 FY2026 common stock issued of $5M fell 84.4% year over year, behind the -18.5% change in trailing-twelve-month common stock issued. Sequentially, it fell 93.8% from the prior quarter.
Context
- Common stock issued amounted to 1.4% of revenue in FY2025, unchanged from a year earlier.
- Common stock issued increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -84.4% toward the trailing-twelve-month pace of -18.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 282M USD
- Year-over-year change
- +22.6%
- 4-year CAGR
- +26.5%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 282M | +22.6% |
| FY2024 | 2024-12-31 | 230M | +26.4% |
| FY2023 | 2023-12-31 | 182M | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 110M | — |
Common Stock Issued vs competitors
How BSX compares with its peers on the latest reported figures
- BSX's LTM Jun 2026 common stock issued of $221M is the 2nd largest of the 11 companies compared; the peer median is $3.49M.
- Its year-over-year change of -18.5% is the 4th highest of 8, against a peer median of -20.8%.
- Common stock issued amounts to 1.1% of revenue for BSX, versus a peer median of 0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $441M | -14.2% | +18.8% | 1.2% | |
| LTM Jun 2026 | $221M | -18.5% | — | 1.1% | |
| LTM Jun 2026 | $155M | +44.7% | — | 2.4% | |
| LTM Jun 2026 | $21.87M | -20.8% | +13.9% | 1.5% | |
| LTM Jun 2026 | $6.72M | — | — | 1.2% | |
| LTM Sep 2026 | $6.03M | -87.3% | +12.0% | 0.4% | |
| LTM Feb 2026 | $950K | +6.1% | — | 0.3% | |
| LTM Mar 2026 | $937K | -97.7% | +139.0% | 1.6% | |
| LTM Sep 2026 | $2K | -93.9% | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BSX) | $3.49M | -20.8% | +16.3% | 0.8% | |
Competitors are the stored peer set for BSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.04B | 698M | 1.59B | 1.85B | 2.89B |
| Depreciation & Amortization | 1.09B | 1.14B | 1.2B | 1.27B | 1.37B |
| Deferred Income Tax | (124M) | (63M) | (1M) | (70M) | (2M) |
| Stock-Based Compensation | 194M | 220M | 233M | 266M | 299M |
| Change in Working Capital | (351M) | (1.01B) | (770M) | (462M) | (246M) |
| Accounts Receivables | (279M) | (220M) | (238M) | (351M) | (269M) |
| Inventory | (346M) | (321M) | (660M) | (228M) | (188M) |
| Accounts Payables | 408M | (255M) | 118M | 243M | 296M |
| Other Working Capital | (134M) | (209M) | 10M | (126M) | (85M) |
| Other Non-Cash Items | 18M | 540M | 253M | 586M | 223M |
| Operating Cash Flow | 1.87B | 1.53B | 2.5B | 3.44B | 4.53B |
| Capital Expenditures | (554M) | (612M) | (800M) | (790M) | (876M) |
| Acquisitions (Net) | (1.43B) | (1.54B) | (1.81B) | (4.64B) | (1.59B) |
| Purchases of Investments | 96M | (24M) | 0 | 0 | 0 |
| Sales of Investments | 294M | 56M | 0 | 0 | 0 |
| Other Investing Activities | (1M) | 106M | (52M) | (257M) | (171M) |
| Investing Cash Flow | (1.6B) | (2.01B) | (2.57B) | (5.69B) | (2.64B) |
| Debt Repayment | 0 | (165M) | (4M) | 1.83B | (491M) |
| Common Stock Issued | 110M | 0 | 182M | 230M | 282M |
| Common Stock Repurchased | 0 | 136M | 0 | 0 | 0 |
| Dividends Paid | (55M) | (55M) | (28M) | 0 | 0 |
| Other Financing Activities | (150M) | (464M) | (145M) | (243M) | (186M) |
| Financing Cash Flow | (95M) | (548M) | 5M | 1.81B | (395M) |
| Effect of Forex Changes | (8M) | (9M) | (16M) | (11M) | 42M |
| Net Change in Cash | 171M | (1.04B) | (82M) | (449M) | 1.54B |
| Free Cash Flow | 1.32B | 914M | 1.7B | 2.65B | 3.66B |
Boston Scientific Corporation
NYSE:BSX
Intrinsic Alpha fair value
Locked
Current Price
$43.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.